Jemal A, Siegel R, Ward E et al.. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717.
Gail MH, Costantino JP, Bryant J et al.. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829–1846.
Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146–151.
White J, Morrow M, Moughan J et al.. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer 2003;97:893–904.
Wilkinson NW, Shahryarinejad A, Winston JS et al.. Concordance with breast cancer pathology reporting practice guidelines. J Am Coll Surg 2003;196:38–43.
Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002;25:235–237.
Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002;137:678–687.
Gundry KR. The application of breast MRI in staging and screening for breast cancer. Oncology (Williston Park) 2005;19:159–169; discussion 170, 173–154, 177.
Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol 2005;23:1601–1602.
Houssami N, Ciatto S, Macaskill P et al.. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;26:3248–3258.
Fischer U, Zachariae O, Baum F et al.. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol 2004;14:1725–1731.
Solin LJ, Orel SG, Hwang WT et al.. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 2008;26:386–391.
Members of the Breast Cancer Disease Site Group. Program in evidence-based care: a Cancer Care Ontario Program. Baseline staging tests in primary breast cancer. Practice guideline report #1-14. April 30, 2003. Available at: http://www.cancercare.on.ca/pdf/pebc1-14f.pdf. Accessed October 3, 2007.
Puglisi F, Follador A, Minisini AM et al.. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005;16:263–266.
Kumar R, Chauhan A, Zhuang H et al.. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98:267–274.
Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET study group. J Clin Oncol 2004;22:277–285.
Podoloff DA, Advani RH, Allred C et al.. NCCN Task Force Report: PET/CT scanning in cancer. J Natl Compr Canc Netw 2007;5(Suppl 1):S1–24.
Carr CE, Conant EF, Rosen MA et al.. The impact of FDG PET in the staging of breast cancer [abstract]. J Clin Oncol 2006:24:18 (Suppl 1):Abstract 530.
Khan QJ, O’Dea AP, Dusing R et al.. Integrated FDG-PET for initial staging of breast cancer [abstract]. J Clin Oncol 2007;25:18(Suppl 1):Abstract 558.
Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. RadiGraphics 2007;27:S215–229.
Wang S, Saboorian MH, Frenkel E et al.. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374–381.
DAKO HercepTest [package insert]. Carpinteria, CA: DAKO Corp; 2004.
Pathway HER2 [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.; 2004.
INFORM HER2/neu gene detection system [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.; 2001.
PathVysion HER2/neu method [package insert]. Downers Grove, IL: Vysis, Inc.; 2001.
SPOT-Light HER2 CISH kit [package insert]. Camarillo, CA: Invitrogen Corp.; 2008.
Anderson S, Gilkerson E, Klein P. Concordance between local labs and a central lab using FISH and IHC for HER2 testing [abstract]. Breast Cancer Res Treat 2002;76:S68:Abstract 235.
Paik S, Bryant J, Tan-Chiu E et al.. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852–854.
Paik S, Tan-Chiu E, Bryant J et al.. Successful quality assurance program for HER2 testing in the NSABP trial for herceptin. Breast Cancer Res and Treat 2002;76(Suppl):S31.
Perez EA, Suman VJ, Davidson NE et al.. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol 2006;24:3032–3038.
Tubbs RR, Pettay JD, Roche PC et al.. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714–2721.
Press MF, Sauter G, Bernstein L et al.. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:6598–6607.
Carlson RW, Moench SJ, Hammond MEH et al.. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(Suppl 3):S1–22.
Wolff AC, Hammond ME, Schwartz JN et al.. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118–147.
Cooke T, Reeves J, Lanigan A, Stanton P. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 2001;12(Suppl 1):S23–28.
Paik S, Bryant J, Park C et al.. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361–1370.
Paik S, Bryant J, Tan-Chiu E et al.. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991–1998.
Piccart MJ, Di Leo A, Hamilton A. HER2 a ‘predictive factor’ ready to use in the daily management of breast cancer patients? Eur J Cancer 2000;36:1755–1761.
Thor AD, Berry DA, Budman DR et al.. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346–1360.
Pritchard KI, Shepherd LE, O’Malley FP et al.. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103–2111.
Dressler LG, Berry DA, Broadwater G et al.. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005;23:4287–4297.
Romond EH, Perez EA, Bryant J et al.. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–1684.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–1672.
Slamon D, Eiermann W, Robert N et al.. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 10–14, 2006; San Antonio, Texas. Abstract 52.
Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al.. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–820.
Cobleigh MA, Vogel CL, Tripathy D et al.. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.
Slamon DJ, Leyland-Jones B, Shak S et al.. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.
Vogel CL, Cobleigh MA, Tripathy D et al.. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719–726.
Allred DC, Harvey JM, Berardo M et al.. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1999;11:155–168.
Rhodes A, Jasani B, Barnes DM et al.. Reliability of immunochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125–130.
Rudiger T, Höfler H, Kreipe HH et al.. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26:873–882.
Arriagada R, Le MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 1996;14:1558–1564.
Clarke M, Collins R, Darby S et al.. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087–2106.
Fisher B, Anderson S, Bryant J et al.. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233–1241.
Veronesi U, Cascinelli N, Mariani L et al.. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227–1232.
McCormick B. Partial-breast radiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. J Natl Compr Canc Netw 2005;3:301–307.
Pignol J-P, Olivotto E, Rakovitch WE et al.. Phase III randomized study of intensity modulated radiation therapy vs. standard wedging adjuvant breast radiotherapy. Int J Rad Oncol 2006;66:S1.
Whelan T, MacKenzie R, Julian J et al.. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002;94:1143–1150.
Antonini N, Jones H, Horiot JC et al.. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881–10882. Radiother Oncol 2007;82:265–271.
Bartelink H, Horiot JC, Poortmans P et al.. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:1378–1387.
Jones H, Antonini N, Colette L et al.. The impact of boost dose and margins on the local recurrence rate in breast conserving therapy: results from the EORTC boost-no-boost trial [abstract]. Int J Radiat Oncol Biol Phys 2007;69(3 Suppl):S2–3.
Fourquet A, Campana F, Zafrani B et al.. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25 year follow-up. Int J Radiat Oncol Biol Phys 1989;17:719–725.
Komoike Y, Akiyama F, Iino Y et al.. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer 2006;106:35–41.
Zhou P, Gautam S, Recht A. Factors affecting outcome for young women with early stage invasive cancer treated with breast-conserving therapy. Breast Cancer Res Treat 2007;101:51–57.
Golshan M, Miron A, Nixon AJ et al.. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg 2006;192:58–62.
Kroman N, Holtveg H, Wohlfahrt J et al.. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 2004;100:688–693.
Hughes KS, Schnaper LA, Berry D et al.. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971–977.
Hughes KS, Schnaper LA, Berry D et al.. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: a report of further follow-up. Presented at the San Antonio Breast Cancer Symposium; December 14, 2006; San Antonio, Texas. Abstract 11.
Fyles AW, McCready DR, Manchul LA et al.. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351:963–970.
Recht A, Come SE, Henderson IC et al.. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334:1356–1361.
Dubey A, Recht A, Come SE et al.. Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. Int J Radiat Oncol Biol Phys 1999;45:877–884.
Markiewicz DA, Schultz DJ, Haas JA et al.. The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. Int J Radiat Oncol Biol Phys 1996;35:661–668.
Abner AL, Recht A, Vicini FA et al.. Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys 1991;21:331–338.
Lyman GH, Giuliano AE, Somerfield MR et al.. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703–7720.
Bass SS, Lyman GH, McCann CR et al.. Lymphatic mapping and sentinel lymph node biopsy. Breast J 1999;5:288–295.
Cox CE. Lymphatic mapping in breast cancer: combination technique. Ann Surg Oncol 2001;8(9 Suppl):67S–70S.
Cox CE, Nguyen K, Gray RJ et al.. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001;67:513–519; discussion 519–521.
Krag D, Weaver D, Ashikaga T et al.. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998;339:941–946.
McMasters KM, Giuliano AE, Ross MI et al.. Sentinel-lymph-node biopsy for breast cancer—not yet the standard of care. N Engl J Med 1998;339:990–995.
O’Hea BJ, Hill AD, El-Shirbiny AM et al.. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423–427.
Veronesi U, Paganelli G, Viale G et al.. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546–553.
Kuehn T, Vogl FD, Helms G et al.. Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol 2004;30:252–259.
Mansel RE, Fallowfield L, Kissin M et al.. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599–609.
Dupont E, Cox C, Shivers S et al.. Learning curves and breast cancer lymphatic mapping: institutional volume index. J Surg Res 2001;97:92–96.
Cox CE, Salud CJ, Cantor A et al.. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg 2001;193:593–600.
Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992;28A:1415–1418.
Kiricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992;69:2496–2501.
Fisher B, Redmond C, Fisher ER et al.. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674–681.
Alkuwari E, Auger M. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients. Cancer 2008;114:89–93.
Fisher B, Bryant J, Wolmark N et al.. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672–2685.
Bear HD, Anderson S, Smith RE et al.. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Protocol B-27. J Clin Oncol 2006;24:2019–2027.
Buzdar AU, Ibrahim NK, Francis D et al.. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676–3685.
Smith IE, Dowsett M, Ebbs SR et al.. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108–5116.
Ellis MJ, Coop A, Singh B et al.. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808–3816.
Hellman S. Stopping metastases at their source. N Engl J Med 1997;337:996–997.
Overgaard M, Jensen MB, Overgaard J et al.. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353:1641–1648.
Ragaz J, Olivotto IA, Spinelli JJ et al.. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005;97:116–126.
Overgaard M, Hansen PS, Overgaard J et al.. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949–955.
Recht A, Edge SB, Solin LJ et al.. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1539–1569.
Theriault R, Buzdar A, Hortobagyi G et al.. Irradiation (XRT) following mastectomy in patients treated with FAC adjuvant therapy—M.D. Anderson experience [abstract]. Proc Am Soc Clin Oncol 1998;17:99a. Abstract 381.
McGuire SE, Gonzolez-Angulo AM, Huang EH et al.. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007;68:1004–1009.
Huang EH, Tucker SL, Strom EA et al.. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004;22:4691–4699.
Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007;82:247–253.
Nielsen HM, Overgaard M, Grau C et al.. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006;24:2268–2275.
Anderson BO, Masetti R, Silverstein MJ, Oncoplastic approaches to the partial mastectomy: an overview of volume displacement techniques. Lancet Oncol 2005;6:145–157.
Huemer GM, Schrenk P, Moser F et al.. Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers. Plast Reconstr Surg 2007;120:390–398.
Malycha PL, Gough IR, Margaritoni M et al.. Oncoplastic breast surgery: a global perspective on practice, availability, and training. World J Surg 2008;32:2570–2577.
Kaur N, Petit JY et al.. Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer. Ann Surg Oncol 2005;12:539–545.
Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001;19:972–979.
Ravdin PM, Siminoff LA, Davis GJ et al.. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980–991.
Olivotto IA, Bajdik CD, Ravdin PM et al.. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:2716–2725.
Loprinzi CL, Ravdin PM. Decision-making for patients with early breast cancer: individualized decisions for and by patients and their physicians. J Natl Compr Canc Netw 2003;1:189–198.
Jeffrey SS, Lonning PE, Hillner BE. Genomics-based prognosis and therapeutic prediction in breast cancer. J Natl Compr Canc Netw 2005;3:291–300.
Sorlie T, Perou CM, Tibshirani R et al.. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869–10874.
Perou CM, Jeffrey SS, van de Rijn M et al.. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:9212–9217.
Sorlie T, Tibshirani R, Parker J et al.. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418–8423.
Wang Y, Klijn JG, Zhang Y et al.. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671–679.
van ‘t Veer LJ, Dai H, van de Vijver MJ et al.. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–536.
van der Vijver MJ, He YD, van’t Veer LJ et al.. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999–2009.
Glas AM, Floore A, Delahaye LJ et al.. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006;7:278–287.
Paik S, Shak S, Tang G et al.. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–2826.
Paik S, Tang G, Shak S et al.. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–3734.
Fan C, Oh DS, Wessels L et al.. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560–569.
Swain SM, Wilson JW, Mamounas EP et al.. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516–523.
Berry D, Cirrincione C, Henderson IC et al.. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658–1667.
Albain K, Barlow W, O’Malley F et al.. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal node positive estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III Intergroup trial 0100 [meeting abstract]. Presented at the San Antonio Breast Cancer Symposium; December 8–11, 2004; San Antonio, Texas. Abstract LBA37.
Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451–1467.
Berry DA, Muss HB, Thor AD et al.. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18:3471–3479.
Eppenberger-Castori S, Kueng W, Benz C et al.. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001;19:645–656.
Knoop AS, Bentzen SM, Nielsen MM et al.. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001;19:3376–3384.
Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000;27(Suppl):46–52; discussion 92–100.
Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:65–77.
De Laurentiis M, Arpino G, Massarelli E et al.. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741–4748.
Paik S, Shak S, Tang G et al.. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [abstract]. J Clin Oncol 2005;23:16(Suppl 1): Abstract 510.
Arpino G, Green SJ, Allred DC et al.. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004;10:5670–5676.
Dowsett M, Allred C, Knox J et al.. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:1059–1065.
Coombes RC, Kilburn LS, Snowdon CF et al.. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007;369:559–570.
Kaufmann M, Jonat W, Hilfrich J et al.. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 2007;25:2664–2670.
Goss PE, Ingle JN, Martino S et al.. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262–1271.
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45–53.
Thurlimann B, Keshaviah A, Coates AS et al.. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–2757.
Baum M, Budzar AU, Cuzick J et al.. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131–2139.
Howell A, Cuzick J, Baum M et al.. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–62.
Duffy S, Jackson TL, Lansdown M et al.. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006;21:545–553.
Fallowfield L, Cella D, Cuzick J et al.. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:4261–4271.
Eastell R, Adams JE, Coleman RE et al.. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051–1057.
Dowsett M, Cuzick J, Howell A, Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer 2001;85:317–324.
Buzdar AU, Guastalla JP, Nabholtz JM et al.. Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer 2006;107:472–480.
Mouridsen H, Keshaviah A, Coates AS et al.. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. 2007; J Clin Oncol 2007;25:5715–5722.
Boccardo F, Rubagotti A, Puntoni M et al.. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138–5147.
Boccardo F, Rubagotti A, Guglielmini P et al.. Switching to anastrozole versus continued treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Ann Oncol 2006;17(Suppl 7):vii10–14.
Coombes RC, Hall E, Gibson LJ et al.. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–1092.
Jakesz R, Jonat W, Gnant M et al.. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455–462.
Jonat W, Gnant M, boccardo F et al.. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006;7:991–996.
Goss PE, Ingle JN, Martino S et al.. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–1802.
Goss PE, PE, Ingle JN, Pater JL et al.. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:1948–1955.
Whelan TJ, Goss PE, Ingle JN et al.. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931–6940.
Perez EA, Josse RG, Pritchard KI et al.. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629–3635.
Braverman AS, Sawhney H, Tendler A et al.. Pre-menopausal serum estradiol (E2) levels may persist after chemotherapy (CT)-induced amenorrhea in breast cancer (BC) [abstract]. Proc Am Soc Clin Oncol 2002;21:Abstract 164.
Smith IE, Dowsett M, Yap YS et al.. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006;24:2444–2447.
Erban JK, Lau J. On the toxicity of chemotherapy for breast cancer—the need for vigilance. J Natl Cancer Inst 2006;98:1096–1097.
Early Breast Cancer Trialists’ Collaborative Group Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930–942
Wood WC, Budman DR, Korzun AH et al.. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253–1259.
Menard S, Valagussa P, Pilotti S et al.. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001;19:329–335.
Muss HB, Thor AD, Berry DA et al.. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260–1266.
Bang SM, Heo DS, Lee KH et al.. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer 2000;89:2521–2526.
Fisher B, Anderson S, Tan-Chiu E et al.. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931–942.
Fisher B, Brown AM, Dimitrov NV et al.. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483–1496.
Fisher B, Anderson S, Wickerham DL et al.. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15:1858–1869.
Henderson IC, Berry DA, Demetri GD et al.. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–983.
Mamounas EP, Bryant J, Lembersky B et al.. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:3686–3696.
Citron ML, Berry DA, Cirrincione C et al.. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431–1439.
Levine MN, Pritchard KI, Bramwell VH et al.. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23:5166–5170.
French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19:602–611.
Piccart MJ, Di Leo A, Beauduin M et al.. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001;19:3103–3110.
Roche H, Fumoleau P, Spielmann M et al.. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006;24:5664–5671.
Martin M, Pienkowski T, Mackey J et al.. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302–2313.
Sparano JA, Wang M, Martino S et al.. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663–1671.
Sparano JA, Wang M, Martino S et al.. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node negative breast cancer [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 8–11, 2005; San Antonio, Texas. Abstract 48.
Jones S, Holmes F, O’Shaughnessey J et al.. Extended follow-up and analysis of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. San Antonio Breast Cancer Symposium; December 13–16, 2007; San Antonio, Texas. Abstract 12.
Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005;353:1652–1654.
Perez EA, Romond EH, Suman VJ et al.. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 512.
Tan-Chiu E, Yothers G, Romond E et al.. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811–7819.
Perez EA, Suman VJ, Davidson NE et al.. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North American Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231–1238.
Geyer CE, Bryant JL, Romond MS et al.. Update of cardiac dysfunction on NSABP-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) paclitaxel (T) vs. AC T with trastuzumab (H). J Clin Oncol 2006;24(Suppl 1):Abstract 581.
Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25:3525–3533.
Smith I, Procter M, Gelber RD et al.. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007:369:29–36.
Norris B, Chia S, Cheang M et al.. Poor 10 yr breast cancer specific survival and relapse free survival for HER2-positive T1pN0 tumors. San Antonio Breast Cancer Symposium; December 10–14, 2006; San Antonio, Texas. Abstract 2031.
Untch M, Gelber RD, Jackisch C et al.. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19:1090–1096.
Hortobagyi GN, Singletary SE, Strom EA. Locally advanced breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
Rosselli Del Turco M, Palli D, Cariddi A et al.. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer Follow-Up. JAMA 1994;271:1593–1597.
Smith TJ, Davidson NE, Schapira DV et al.. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999;17:1080–1082.
The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 1994;271:1587–1592.
Bast RC Jr, Ravdin P, Hayes DF et al.. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865–1878.
Kirova YM, Stoppa-Lyonnet D, Savignoni A et al.. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005;41:2304–2311.
Pierce LJ, Levin AM, Rebbeck TR et al.. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006;24:2437–2443.
Metcalfe K, Lynch HT, Ghadirian P et al.. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328–2335.
American College of Obstetrics and Gynecology Committee on Gynecologic Practice. ACOG Committee Opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol 2006;107:1475–1478.
Loprinzi CL, Kugler JW, Sloan JA et al.. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–2063.
Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst 2005;97:412–413.
Jin Y, Desta Z, Stearns V et al.. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30–39.
Hillner BE, Ingle JN, Chlebowski RT et al.. American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–4057.
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–497.
Eubank WB, Mankoff D, Bhattacharya M et al.. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004;183:479–486.
Moon DH, Maddahi J, Silverman DH et al.. Accuracy of whole-body fluorine-18-FDG PRT for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431–435.
Vernon CC, Hand JW, Field SB et al.. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996;35:731–744.
Jones EL, Oleson JR, Prosnitz LR et al.. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005;23:3079–3085.
Higgins MJ, Wolff AC. Therapeutic options in the management of metastatic breast cancer. Oncology 2008;22:614–623; discussion 623, 627–629.
Theriault RL, Biermann JS, Brown E et al.. NCCN Task Force Report: Bone Health and Cancer Care. J Natl Compr Canc Netw 2006;(4 Suppl 2):S1–20.
Conte PF, Latreille J, Mauriac L et al.. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996;14:2552–2559.
Hortobagyi GN, Theriault RL, Lipton A et al.. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038–2044.
Theriault RL, Lipton A, Hortobagyi GN et al.. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846–854.
Berenson JR, Rosen LS, Howell A et al.. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191–1200.
Ali SM, Esteva FJ, Hortobagyi G et al.. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001;19:3434–3437.
Theriault RL. The role of bisphosphonates in breast cancer. J Natl Compr Canc Netw 2003;1:232–241.
Rosen LS, Gordon D, Kaminski M et al.. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377–387.
Rosen LS, Gordon DH, Dugan W Jr et al.. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36–43.
Lipton A, Theriault RL, Hortobagyi GN et al.. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082–1090.
Hortobagyi GN, Theriault RL, Porter L et al.. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785–1971.
Diel IJ, Body JJ, Lichinitser MR et al.. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004;40:1704–1712.
McLachlan SA, Cameron D, Murray R et al.. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Investig 2006;26:43–48.
Pecherstorfer M, Rivkin S, Body JJ et al.. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 2006;26:315–322.
Lipton A, Theriault RL, Hortobagyi GN et al.. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082–1090.
Rosen LS, Gordon D, Kaminski M et al.. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735–1744.
Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007;99:1016–1024.
Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Systematic Review Bisphosphonates Osteonecrosis of the Jaw. Ann Intern Med 2006;144:753–761.
Buzdar A, Douma J, Davidson N et al.. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357–3366.
Buzdar AU, Jonat W, Howell A et al.. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:1142–1152.
Bonneterre J, Thurlimann B, Robertson JF et al.. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748–3757.
Nabholtz JM, Buzdar A, Pollak M et al.. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758–3767.
Vergote I, Bonneterre J, Thurlimann B et al.. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Eur J Cancer 2000;36(Suppl 4):S84–85.
Paridaens R, Therasse P, Dirix L et al.. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)—a randomized phase III trial of the EORTC Breast Group [abstract]. J Clin Oncol 2004;22:14S (Suppl 1):Abstract 515.
Klijn JG, Blamey RW, Boccardo F et al.. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343–353.
Osborne CK, Pippen J, Jones SE et al.. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386–3395.
Howell A, Robertson JF, Quaresma Albano J et al.. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396–3403.
Robertson JF, Osborne CK, Howell A et al.. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229–238.
Ingle JN, Suman VJ, Rowland KM et al.. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006;24:1052–1056.
Chia S, Gradishar W, Mauriac L et al.. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664–1670.
Lonning PE, Bajetta E, Murray R et al.. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:2234–2244.
Dombernowsky P, Smith I, Falkson G et al.. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453–461.
Buzdar A, Jonat W, Howell A et al.. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:2000–2011.
Carrick S, Parker S, Wilcken N et al.. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005;2:CD003372.
Sledge GW, Neuberg D, Bernardo P et al.. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 2003;21:588–592.
O’Shaughnessy J, Miles D, Vukelja S et al.. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812–2823.
Albain K, Nag S, Calderillo-Ruiz J et al.. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer. (MBC): First report of overall survival [abstract]. J Clin Oncol 2004;22:14s(Suppl 1):Abstract 510.
Muss HB, Case LD, Richards F II et al.. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991:325;1342–1348.
Falkson G, Gelman R, Pandya K et al.. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998;16:1669–1676.
Miller KD, Wang M, Gralow J et al.. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–2676.
Roche H, Yelle L, Cognetti F et al.. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415–3420.
Thomas E, Tabernero J, Fornier M et al.. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399–3406.
Perez EA, Lerzo G, Pivot X et al.. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407–3414.
Thomas ES, Gomez HL, Li RK et al.. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210–5217.
Seidman AD, Berry D, Cirrincione C et al.. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER2 overexpressors and random assignment to trastuzumab or not in HER2 nonoverexpressors: final results of Cancer and Leukemia Groups B protocol 9840. J Clin Oncol 2008;26:1642–1649.
Roche PC, Suman VJ, Jenkins RB et al.. Concordance between local and central laboratory HER2 testing in the breast Intergroup trial N9831. J Natl Cancer Inst 2002;94:855–857.
Robert N, Leyland-Jones B, Asmar K et al.. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786–2792.
Burstein HJ, Keshaviah A, Baron AD et al.. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110:965–972.
Yamamoto D, Iwase S, Kitamura K et al.. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network 00 trial. Cancer Chemother Pharmacol 2008;61:509–514.
Schaller G, Bangemann N, Weber J et al.. Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer [abstract]. J Clin Oncol 2005;23:18(Suppl 1):Abstract 717.
Seidman A, Hudis C, Pierri MK et al.. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215–1221.
Bartsch R, Wenzel C, Altorjai G et al.. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007;25:3853–3858.
Von Minckwitz G, Vogel P, Schmidt M et al.. Trastuzumab treatment beyond progression in patients with HER2 positive metastatic breast cancer—interim report [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4056.
Von Minckwitz G, Zielinski C, Maarteense E et al.. Capecitabine vs. Capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 1025.